Blue Earth Therapeutics completes £60m Series A to accelerate development of next generation targeted radioligand therapies

Blue Earth Therapeutics develops targeted radioligand therapies that deliver radiation directly to tumours, focusing initially on prostate cancer while minimising damage to surrounding healthy tissue.